$5650 | Single User
$6650 | Multi User
$8150 | Corporate License
$10000 | Enterprise License

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021
[Published by MarketsandMarkets]

Published by MarketsandMarkets: 15 Sep 2016 | 19997 | In Stock
Related Topics: Antibodies , AstraZeneca , Breast Cancer , Cancer , Colorectal Cancer , Immunotherapy , Lilly , Lung Cancer , Melanoma , Novartis , Pfizer , Prostate Cancer , Roche , Vaccine

Introduction

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries are driving growth in the caner immunotherapy market. However, stringent regulatory policies and side-effects associated with cancer therapy are the major factors restraining the growth of this market.

The global cancer immunotherapy market has been segmented on the basis of type, application, end user, and region. The monoclonal antibodies segment is expected to register the highest growth rate in the cancer immunotherapy market, by type, during the forecast period. Factors such as high success rate and less recovery time are contributing to the high growth in this segment.

Based on application, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others (renal cell carcinoma, cervical, gastric, and lymphoma). The lung cancer segment is expected to witness the highest CAGR from 2016 to 2021, primarily due to the rising prevalence of this type of cancer.

Based on end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global cancer immunotherapy market in 2016. The rise in healthcare spending has resulted in the increasing use of drugs in hospitals.

Geographically, the cancer immunotherapy market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). The large share of North America can be attributed to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity.

Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output, in order to remain successful in the cancer immunotherapy market.

The major players in the cancer immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).

OBJECTIVES OF THE STUDY

• To define, describe, and forecast the global cancer immunotherapy market on the basis of type, application, end user, and region

• To provide detailed information regarding the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the global cancer immunotherapy market

• To strategically analyze the markets with respect to their individual growth trends, future prospects, and contributions to the total market

• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders

• To forecast the revenue of market segments with respect to four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)

• To profile the key players and comprehensively analyze their market shares and core competencies

• To analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; and R&D activities in the global cancer immunotherapy market

Target Audience for this Report:

• Drug Manufacturers and Suppliers

• Academic Research Institutes

• Hospitals and Clinics

• Research and Development (R&D) Companies

• Business Research and Consulting Service Providers

• Medical Research Laboratories

• Academic Medical Centers and Universities

Scope of the Report:

In this report, the cancer immunotherapy market has been segmented into the following segments and subsegments:

Cancer Immunotherapy Market, by Type

• Monoclonal Antibodies

• Cancer Vaccines

• Checkpoint Inhibitors

• Immunomodulators

Cancer Immunotherapy Market, by Application

• Lung Cancer

• Breast Cancer

• Head and Neck Cancer

• Prostate Cancer

• Colorectal Cancer

• Melanoma

• Others

Cancer Immunotherapy Market, by End User

• Hospitals

• Clinics & Others

Cancer Immunotherapy Market, by Region

• North America

o U.S.

o Canada

• Europe

o Germany

o France

o Italy

o U.K.

o Spain

o RoE

• APAC

o India

o China

o Japan

o RoAPAC

• Rest of the World (RoW)

o South America, Central America, and the Caribbean

o Oceania

o Africa

Table of Contents
for Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021 [Published by MarketsandMarkets]

  • TABLE OF CONTENTS

    1 INTRODUCTION 14

    1.1 OBJECTIVES OF THE STUDY 14

    1.2 MARKET DEFINITION 14

    1.3 MARKETS COVERED 15

    1.3.1 YEARS CONSIDERED FOR THE STUDY 16

    1.4 CURRENCY 17

    1.5 STAKEHOLDERS 17

    2 RESEARCH METHODOLOGY 18

    2.1 MARKET SIZE ESTIMATION 19

    2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22

    2.3 MARKET SHARE ESTIMATION 23

    2.3.1 KEY DATA FROM SECONDARY SOURCES 23

    2.3.2 KEY DATA FROM PRIMARY SOURCES 24

    2.4 ASSUMPTIONS FOR THE STUDY 24

    3 EXECUTIVE SUMMARY 25

    3.1 INTRODUCTION 25

    3.2 CURRENT SCENARIO 25

    3.3 FUTURE OUTLOOK 26

    4 PREMIUM INSIGHTS 30

    4.1 LUCRATIVE OPPORTUNITIES IN THE CANCER IMMUNOTHERAPY MARKET 30

    5 MARKET OVERVIEW 34

    5.1 INTRODUCTION 35

    5.1.1 DRIVERS 36

    5.1.1.1 Rise in incidence rate of cancer worldwide 36

    5.1.1.2 Increase in adoption of immunotherapy over other treatment options 36

    5.1.1.3 Development of bioinformatics tools are enhancing drug development process 37

    5.1.2 RESTRAINTS 37

    5.1.2.1 High cost of treatment 37

    5.1.3 OPPORTUNITIES 37

    5.1.3.1 Increase in clinical trials against several types of cancers in immunotherapy 37

    5.1.3.2 High growth projections in the developing countries 38

    5.1.4 CHALLENGES 38

    5.1.4.1 Availability of Limited funds to initiate clinical trials 38

    5.1.4.2 Complexity of cancer may limit the immune response 38

    5.2 OVERVIEW OF GLOBAL CANCER IMMUNOTHERAPY FUNDING 39

    6 INDUSTRY TRENDS 42

    6.1 GLOBAL TRENDS IN CANCER IMMUNOTHERAPY MARKET 42

    6.1.1 OPDIVO (NIOLUMAB) AND KEYTRUDA (PEMBROLIZUMAB) FDA APPROVAL IN U.S. INCREASES HOPE AMONGST LUNG CANCER PATIENTS 42

    6.1.2 COMBINATION IMMUNOTHERAPY POTENTIAL WAY TO TREAT MELANOMA 42

    6.1.3 U.S. CANCER IMMUNOTHERAPY RESEARCH COMMUNITY BUILDS HOPE TO COMBAT CANCER BY 2020 42

    6.1.4 U.K. SCIENTISTS PROJECT A CHANGE IN THE MEANS OF TREATMENT FOR CANCER WITH QUALITY THERAPIES 43

    6.1.5 WORLD IS MOVING TOWARD PERSONALIZED IMMUNOTHERAPY 43

    6.1.6 A COMBINATION OF MODERN IMMUNOTHERAPY AND TRADITIONAL CHINESE MEDICINES CONTINUES TO INCREASE SURVIVAL RATE OF PATIENTS IN CHINA 43

    6.2 PRICING VARIATIONS IN GLOBAL CANCER IMMUNOTHERAPY MARKET 44

    6.3 SMALL PLAYERS GETTING TOGETHER TO MAKE LONG TERM IMPACT IN CANCER IMMUNOTHERAPY MARKET 45

    6.4 ATTRACTIONS FOR PHARMACEUTICAL INDUSTRY 46

    6.5 HEAT MAP FOR VARIATIONS IN CANCER IMMUNOTHERAPY FOR DIFFERENT TYPES OF CANCERS 47

    6.5.1 BREAST CANCER 47

    6.5.2 LUNG CANCER 48

    6.5.3 MULTIPLE MYELOMA 49

    6.5.4 LYMPHOMA 50

    7 CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE 53

    7.1 INTRODUCTION 54

    7.2 MONOCLONAL ANTIBODIES 55

    7.2.1 NAKED MONOCLONAL ANTIBODIES 57

    7.2.2 CONJUGATED MONOCLONAL ANTIBODIES 58

    7.2.3 BISPECIFIC MONOCLONAL ANTIBODIES 59

    7.3 VACCINES 59

    7.3.1 PROPHYLACTIC VACCINES 61

    7.3.2 THERAPEUTIC VACCINES 62

    7.4 CHECK POINT INHIBITORS 63

    7.4.1 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 64

    7.4.2 PROGRAMMED DEATH 1 (PD-1) AND PROGRAMMED DEATH LIGAND 1 (PD-L1) 65

    7.5 CELL THERAPIES 66

    7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 66

    7.5.2 DENDRITIC CELLS 66

    7.6 IMMUNOMODULATORS 67

    7.6.1 GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR

    (GM-CSF & G-CSF) 69

    7.6.2 INTERFERONS (IFN) 69

    7.6.3 INTERLEUKINS (IL) 70

    7.6.4 ONCOLYTIC VIRUS 71

    7.6.4.1 Immunotherapy 71

    7.6.4.1 Immunity as an obstacle 71

    7.6.4.2 Immunity as an ally 71

    7.6.4.3 Approved Products & Clinical Trails 71

    8 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 72

    8.1 INTRODUCTION 73

    8.2 LUNG CANCER 74

    8.3 BREAST CANCER 75

    8.4 MULTIPLE MYELOMA 77

    8.5 COLORECTAL CANCER 78

    8.6 HEAD & NECK CANCER 79

    8.7 PROSTATE CANCER 80

    8.8 MELANOMA 81

    8.9 OTHER CANCER TYPES 83

    9 CANCER IMMUNOTHERAPY MARKET, BY END USER 84

    9.1 INTRODUCTION 85

    9.2 HOSPITAL 86

    9.3 CLINICS AND OTHERS 87

    10 CANCER IMMUNOTHERAPY MARKET, BY REGION 88

    10.1 INTRODUCTION 89

    10.2 NORTH AMERICA 91

    10.3 EUROPE 94

    10.4 ASIA-PACIFIC 96

    10.5 REST OF THE WORLD (ROW) 99

    11 COMPETITIVE LANDSCAPE 100

    11.1 OVERVIEW 101

    11.2 MARKET SHARE ANALYSIS 102

    11.3 COMPETITIVE SITUATION AND TRENDS 103

    11.3.1 APPROVALS 103

    11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 105

    11.3.3 ACQUISITIONS 107

    11.3.4 EXPANSIONS 108

    11.3.5 OTHER DEVELOPMENTS 108

    12 COMPANY PROFILE 109

    (Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*

    12.1 AMGEN INC. 109

    12.2 ASTRAZENECA 112

    12.3 BAYER AG 114

    12.4 BRISTOL-MYERS SQUIBB 117

    12.5 ELI LILLY AND COMPANY 120

    12.6 JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON) 123

    12.7 MERCK 126

    12.8 NOVARTIS 129

    12.9 PFIZER 132

    12.10 F. HOFFMANN-LA ROCHE LTD 134

    *Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

    13 APPENDIX 137

    13.1 INSIGHTS FROM INDUSTRY EXPERTS 137

    13.2 DISCUSSION GUIDE 138

    13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 141

    13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 143

    13.5 AVAILABLE CUSTOMIZATIONS 144

    13.6 RELATED REPORTS 145

List Of Tables
in Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021 [Published by MarketsandMarkets]

LIST OF TABLES


TABLE 1 OVERVIEW OF FUNDING PATTERN IN DIFFERENT TYPES OF CANCER BY NIH, U.S., 2012–2017 (USD MILLION) 39

TABLE 2 OVERVIEW OF KEY FUNDING IN CANCER IMMUNOTHERAPY MARKET, 2016 40

TABLE 3 CONVENTIONAL CANCER THERAPY VERSUS CANCER IMMUNOTHERAPY 41

TABLE 4 CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE,

2014–2021 (USD MILLION) 55

TABLE 5 CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBTYPE,

2014–2021 (USD MILLION) 56

TABLE 6 CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION,

2014–2021 (USD MILLION) 57

TABLE 7 NAKED MONOCLONAL ANTIBODIES MARKET, BY REGION,

2014–2021 (USD MILLION) 58

TABLE 8 CONJUGATED MONOCLONAL ANTIBODIES MARKET, BY REGION,

2014–2021 (USD MILLION) 58

TABLE 9 BISPECIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION,

2014–2021 (USD MILLION) 59

TABLE 10 VACCINES MARKET, BY SUBTYPE, 2014–2021 (USD MILLION) 60

TABLE 11 VACCINES MARKET, BY REGION, 2014–2021 (USD MILLION) 61

TABLE 12 PROPHYLACTIC VACCINES MARKET SIZE, 2014–2021 (USD MILLION) 62

TABLE 13 THERAPEUTIC VACCINES MARKET, BY REGION, 2014–2021 (USD MILLION) 62

TABLE 14 CHECKPOINT INHIBITORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION) 63

TABLE 15 CHECKPOINT INHIBITORS MARKET, BY REGION, 2014–2021 (USD MILLION) 64

TABLE 16 CYTOXIC T-LYMPHOCYTE MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 65

TABLE 17 CYTOXIC T-LYMPHOCYTE MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 65

TABLE 18 IMMUNOMODULATORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION) 67

TABLE 19 IMMUNOMODULATORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 68

TABLE 20 GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 69

TABLE 21 INTERFERONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 70

TABLE 22 INTERLEUKINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 70

TABLE 23 CANCER IMMUNOTHERAPY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 74

TABLE 24 LUNG CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 75

TABLE 25 BREAST CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 76

TABLE 26 MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 77

TABLE 27 COLORECTAL CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 78

TABLE 28 HEAD & NECK CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 80

TABLE 29 PROSTATE CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 81

TABLE 30 MELANOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 82

TABLE 31 OTHER TYPES OF CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 83

TABLE 32 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER,

2014–2021 (USD MILLION) 85

TABLE 33 HOSPITALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 86

TABLE 34 CLINICS AND OTHERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 87

TABLE 35 CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 90

TABLE 36 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION) 93

TABLE 37 EUROPE: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE,

2014–2021 (USD MILLION) 95

TABLE 38 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION) 98

TABLE 39 ROW: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE,

2014–2021 (USD MILLION) 99

TABLE 40 APPROVALS, 2013–2016 103

TABLE 41 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013–2016 105

TABLE 42 ACQUISITIONS, 2013–2016 107

TABLE 43 EXPANSIONS, 2013–2016 108

List Of Figures, Charts and Diagrams
in Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021 [Published by MarketsandMarkets]

LIST OF FIGURES


FIGURE 1 CLASSIFICATION OF CANCER IMMUNOTHERAPY 15

FIGURE 2 RESEARCH DESIGN 18

FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 20

FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 20

FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 21

FIGURE 6 DATA TRIANGULATION METHODOLOGY 22

FIGURE 7 THE MONOCLONAL ANTIBODY SEGMENT IS EXPECTED TO LEAD THE GLOBAL CANCER IMMUNOTHERAPY MARKET DURING THE FORECAST PERIOD 26

FIGURE 8 THE LUNG CANCER SEGMENT TO LEAD THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2016 27

FIGURE 9 HOSPITALS ARE MAJOR END USERS OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET 27

FIGURE 10 NORTH AMERICA LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015 28

FIGURE 11 FUTURE OF CANCER IMMUNOTHERAPEUTICS 29

FIGURE 12 GLOBAL CANCER IMMUNOTHERAPY MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 30

FIGURE 13 LUNG CANCER APPLICATION DOMINATED THE GLOBAL CANCER IMMUNOTHERAPY MARKET, 2016 31

FIGURE 14 ASIA-PACIFIC TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD 32

FIGURE 15 LUNG CANCER TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD IN THE CANCER IMMUNOTHERAPY MARKET 33

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35

FIGURE 17 POPULATION FORECASTS FOR ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER, 2012 VS. 2020 36

FIGURE 18 PRICING TREND OF IMBRUVICA ACROSS MAJOR PHARMACEUTICAL MARKET

IN 2016 44

FIGURE 19 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR BREAST CANCER 47

FIGURE 20 ANNUAL COST OF BREAST CANCER IMMUNOTHERAPY, 2016 48

FIGURE 21 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LUNG CANCER 48

FIGURE 22 ANNUAL COST OF LUNG CANCER IMMUNOTHERAPY, 2016 49

FIGURE 23 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR MULTIPLE MYELOMA 49

FIGURE 24 ANNUAL COST OF MULTIPLE MYELOMA IMMUNOTHERAPY, 2016 50

FIGURE 25 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LYMPHOMA 50

FIGURE 26 ANNUAL COST OF LYMPHOMA IMMUNOTHERAPY, 2016 51

FIGURE 27 CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE 54

FIGURE 28 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET SIZE IN 2016 55

FIGURE 29 NAKED MONOCLONAL ANTIBODIES TO ACCOUNT FOR THE LARGEST

SHARE IN 2016 56

FIGURE 30 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER MONOCLONAL ANTIBODIES MARKET IN 2016 57

FIGURE 31 VACCINES MARKET SIZE, BY SUBTYPE, 2016–2021 (USD MILLION) 60

FIGURE 32 ASIA-PACIFIC EXPECTED TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE VACCINES MARKET 61

FIGURE 33 PROGRAMMED DEATH 1(PD-1) IS EXPECTED TO BE THE FASTEST-GROWING SEGMENT OF THE CHECK POINT INHIBITORS MARKET 63

FIGURE 34 ROW IS EXPECTED TO ACCOUNT THE FASTEST-GROWING REGIONAL SEGMENT OF THE CHECKPOINT INHIBITORS MARKET 64

FIGURE 35 GM-CSF & G-CSF SEGMENT IS EXPECTED TO DOMINATE THE IMMUNOMODULATORS MARKET IN 2016 67

FIGURE 36 NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE IMMUNOMODULATORS MARKET THROUGH 2021 68

FIGURE 37 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 73

FIGURE 38 LUNG CANCER SEGMENT LEADS THE CANCER IMMUNOTHERAPY MARKET

SIZE IN 2016 73

FIGURE 39 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE LUNG CANCER IMMUNOTHERAPY MARKET IN 2016 75

FIGURE 40 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER IN 2016 76

FIGURE 41 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR MULTIPLE MYELOMA IN 2016 77

FIGURE 42 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER IN 2016 78

FIGURE 43 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER IN 2016 79

FIGURE 44 NORTH AMERICA ESTIMATED TO DOMINATE THE IMMUNOTHERAPY MARKET FOR PROSTATE CANCER IN 2016 80

FIGURE 45 NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE CANCER IMMUNOTHERAPY MARKET FOR MELANOMA DURING THE FORECAST PERIOD 82

FIGURE 46 ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE IMMUNOTHERAPY MARKET FOR OTHER CANCER TYPES, 2016-2021 83

FIGURE 47 CANCER IMMUNOTHERAPY MARKET, BY END USER,

2016 VS. 2021 (USD MILLION) 85

FIGURE 48 HOSPITALS MARKET SIZE, 2016 VS. 2021, BY REGION (USD MILLION) 86

FIGURE 49 CLINICS AND OTHERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION) 87

FIGURE 50 GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION DURING THE FORECAST PERIOD 89

FIGURE 51 CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO GROW AT THE HIGHEST RATE FROM 2016 TO 2021 90

FIGURE 52 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016 92

FIGURE 53 THE CHECK POINT INHIBITORS IS PROJECTED TO BE THE FASTEST-GROWING MARKET IN NORTH AMERICA DURING THE FORECAST PERIOD 93

FIGURE 54 MONOCLONAL ANTIBODIES SEGMENT IS PROJECTED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN EUROPE TILL 2021 95

FIGURE 55 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016 97

FIGURE 56 CHECKPOINT INHIBITORS SEGMENT IS EXPECTED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN THE ROW REGION TILL 2021 99

FIGURE 57 COMPANIES ADOPTED APPROVALS AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 101

FIGURE 58 GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2015 102

FIGURE 59 APPROVALS: THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2013 TO 2015 103

FIGURE 60 AMGEN: COMPANY SNAPSHOT 109

FIGURE 61 ASTRAZENECA: COMPANY SNAPSHOT 112

FIGURE 62 BAYER AG: COMPANY SNAPSHOT 114

FIGURE 63 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT 117

FIGURE 64 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 120

FIGURE 65 JANSSEN GLOBAL SERVICES, LLC: COMPANY SNAPSHOT 123

FIGURE 66 MERCK: COMPANY SNAPSHOT 126

FIGURE 67 NOVARTIS; COMPANY SNAPSHOT 129

FIGURE 68 PFIZER : COMPANY SNAPSHOT 132

FIGURE 69 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 134

Additional Details

Publisher

MarketsandMarkets

Publisher Information

Reference

19997 | BT 4576

Number of Pages

147

Report Format

PDF

MarketsandMarkets Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?
Scope Top-line data from the ExteNET study – which were released earlier this week – appear to estab...
28 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info
The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus
IntroductionThere has been considerable media hype and clinical interest in cancer immunotherapy in ...
01 Jul 2014 by FirstWord Pharma USD $4,995 More Info
Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
28 Apr 2014 by FirstWord Pharma USD $695 More Info
Breast Cancer: New targeted therapies transform treatment - KOL Insight
IntroductionThe introduction of targeted therapies revolutionised the breast cancer market, widening...
10 Feb 2014 by FirstWord Pharma USD $7,900 More Info
Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?
Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget...
01 Dec 2013 by FirstWord Pharma USD $695 More Info
KOL Insight: Prostate Cancer: Competition intensifies in race to the top
IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The...
01 Nov 2013 by FirstWord Pharma USD $7,900 More Info
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top
IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
01 Nov 2013 by FirstWord Pharma USD $4,995 More Info
Colorectal Cancer -- KOL Insight Module
IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift du...
01 Oct 2013 by FirstWord Pharma USD $7,900 More Info
Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?
ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
01 Oct 2013 by FirstWord Pharma USD $695 More Info

This report is published by MarketsandMarkets

Download Free Report Summary PDF

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021 [Published by MarketsandMarkets] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...